MX2020002042A - Anticuerpos anti-apelin y sus usos. - Google Patents
Anticuerpos anti-apelin y sus usos.Info
- Publication number
- MX2020002042A MX2020002042A MX2020002042A MX2020002042A MX2020002042A MX 2020002042 A MX2020002042 A MX 2020002042A MX 2020002042 A MX2020002042 A MX 2020002042A MX 2020002042 A MX2020002042 A MX 2020002042A MX 2020002042 A MX2020002042 A MX 2020002042A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- retinopathy
- diabetic
- neovascularization
- cancer
- Prior art date
Links
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 6
- 208000002780 macular degeneration Diseases 0.000 abstract 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 2
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 abstract 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 201000007917 background diabetic retinopathy Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 201000000159 corneal neovascularization Diseases 0.000 abstract 2
- 201000011190 diabetic macular edema Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 abstract 2
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 2
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010065630 Iris neovascularisation Diseases 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010046788 Uterine haemorrhage Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006828 endometrial hyperplasia Diseases 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002632 myometrial effect Effects 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 201000008979 rubeosis iridis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549523P | 2017-08-24 | 2017-08-24 | |
| US201762579287P | 2017-10-31 | 2017-10-31 | |
| US201862656586P | 2018-04-12 | 2018-04-12 | |
| US201862658111P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/047144 WO2019040390A1 (en) | 2017-08-24 | 2018-08-21 | ANTI-APELIN ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002042A true MX2020002042A (es) | 2020-08-13 |
Family
ID=65440110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002042A MX2020002042A (es) | 2017-08-24 | 2018-08-21 | Anticuerpos anti-apelin y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11365242B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3672987B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7219265B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200038311A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111032689B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018322452A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020003584A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3072261A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272476A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020002042A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202000899PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019040390A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119613548A (zh) * | 2018-06-13 | 2025-03-14 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| US20220220214A1 (en) * | 2019-06-19 | 2022-07-14 | Ab Initio Biotherapeutics, Inc. | Apj modulators and uses thereof |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| CN112442534B (zh) * | 2020-11-06 | 2022-03-15 | 温州医科大学 | 循环血外泌体miR-146a-5p作为视网膜静脉阻塞治疗及预后评估标志物中的应用 |
| CN114539415B (zh) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 |
| CN112480267A (zh) * | 2020-12-04 | 2021-03-12 | 复旦大学附属华山医院 | 一种可特异性识别增殖状态内皮细胞的启动分子及工程细胞 |
| CN112546198B (zh) * | 2020-12-17 | 2022-03-25 | 温州医科大学慈溪生物医药研究院 | 一种用于治疗脑中风和急性脑梗的药物组合物 |
| CN114099642A (zh) * | 2021-11-12 | 2022-03-01 | 南通大学 | 基因Apln在制备治疗与细胞成血管有关疾病药物中的应用 |
| CN114031686A (zh) * | 2021-12-23 | 2022-02-11 | 杭州百凌生物科技有限公司 | 一种四型胶原蛋白ɑ5的抗体、检测试剂盒及其应用 |
| CN120058948B (zh) * | 2023-11-30 | 2025-12-30 | 粤港澳大湾区精准医学研究院(广州) | 一种抗人her2的单克隆抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946382B2 (en) * | 2009-02-27 | 2015-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apelin peptides and methods of use |
| US9156911B2 (en) | 2011-07-18 | 2015-10-13 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| JP6181152B2 (ja) * | 2012-04-11 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | アペリン阻害剤としてのポリペプチドおよびその使用 |
| AU2014236451B2 (en) * | 2013-03-14 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| RU2015155601A (ru) | 2013-06-10 | 2017-07-14 | Мерк Шарп И Доум Корп. | Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки |
-
2018
- 2018-08-21 AU AU2018322452A patent/AU2018322452A1/en not_active Abandoned
- 2018-08-21 MX MX2020002042A patent/MX2020002042A/es unknown
- 2018-08-21 BR BR112020003584-0A patent/BR112020003584A2/pt not_active IP Right Cessation
- 2018-08-21 US US16/639,808 patent/US11365242B2/en active Active
- 2018-08-21 JP JP2020511350A patent/JP7219265B2/ja active Active
- 2018-08-21 EP EP18848958.7A patent/EP3672987B1/en active Active
- 2018-08-21 CN CN201880055019.2A patent/CN111032689B/zh active Active
- 2018-08-21 KR KR1020207008305A patent/KR20200038311A/ko not_active Withdrawn
- 2018-08-21 CA CA3072261A patent/CA3072261A1/en active Pending
- 2018-08-21 SG SG11202000899PA patent/SG11202000899PA/en unknown
- 2018-08-21 WO PCT/US2018/047144 patent/WO2019040390A1/en not_active Ceased
-
2020
- 2020-02-05 IL IL272476A patent/IL272476A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019040390A1 (en) | 2019-02-28 |
| AU2018322452A1 (en) | 2020-03-05 |
| SG11202000899PA (en) | 2020-03-30 |
| EP3672987B1 (en) | 2025-04-16 |
| EP3672987C0 (en) | 2025-04-16 |
| CN111032689A (zh) | 2020-04-17 |
| JP2020536492A (ja) | 2020-12-17 |
| JP7219265B2 (ja) | 2023-02-07 |
| CN111032689B (zh) | 2024-02-27 |
| EP3672987A1 (en) | 2020-07-01 |
| IL272476A (en) | 2020-03-31 |
| US11365242B2 (en) | 2022-06-21 |
| CA3072261A1 (en) | 2019-02-28 |
| US20200362021A1 (en) | 2020-11-19 |
| EP3672987A4 (en) | 2021-08-18 |
| BR112020003584A2 (pt) | 2020-09-01 |
| KR20200038311A (ko) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002042A (es) | Anticuerpos anti-apelin y sus usos. | |
| JP2020536492A5 (cg-RX-API-DMAC7.html) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| MX2020012588A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos. | |
| CN111356476A (zh) | Lag-3抗体药物组合物及其用途 | |
| EA201391812A1 (ru) | Отдельные вариабельные домены против vegf, слитые с fc-доменами | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP7471227B2 (ja) | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 | |
| KR20160146770A (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| AR076796A1 (es) | Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento. | |
| RU2018121619A (ru) | Pd1/ctla4-связывающие вещества | |
| JP2017506217A5 (cg-RX-API-DMAC7.html) | ||
| MX2022001433A (es) | Tratamiento personalizado de enfermedades oftalmologicas. | |
| HRP20190817T1 (hr) | Ang2-vezujuće molekule | |
| JP2021506922A5 (cg-RX-API-DMAC7.html) | ||
| PH12021551153A1 (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists | |
| MX2020010968A (es) | Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades. | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| EA202192757A1 (ru) | Способ лечения опухолей | |
| JP2013542228A5 (cg-RX-API-DMAC7.html) | ||
| PH12019501530A1 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNFa | |
| JP2015083565A5 (cg-RX-API-DMAC7.html) | ||
| JP2011503094A5 (cg-RX-API-DMAC7.html) | ||
| EA202090531A1 (ru) | Антитела к апелину и их применение |